No differences in response rate (RR), progression-free survival (PFS), overall survival (OS) and quality of life (QoL) were seen in patients randomly treated with biweekly oxaliplatin plus either fluorouracil/folinic acid or capecitabine.
Comella, P., Casaretti, R., Manzo, R., Sandomenico, C., Licenziato, M., Avallone, A., et al. (2010). Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet. ACTA ONCOLOGICA, 49(1), 50-56 [10.3109/02841860903369540].
Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet
ROSELLI, MARIO
2010-01-01
Abstract
No differences in response rate (RR), progression-free survival (PFS), overall survival (OS) and quality of life (QoL) were seen in patients randomly treated with biweekly oxaliplatin plus either fluorouracil/folinic acid or capecitabine.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet.pdf
accesso aperto
Dimensione
233.9 kB
Formato
Adobe PDF
|
233.9 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.